Skip to content
2000
Volume 20, Issue 11
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Protein tyrosine phosphatase 2 (SHP-2) has long been proposed as a cancer drug target. Several small-molecule compounds with different mechanisms of SHP-2 inhibition have been reported, but none are commercially available. Pool selectivity over protein tyrosine phosphatase 1 (SHP-1) and a lack of cellular activity have hindered the development of selective SHP-2 inhibitors. In this review, we describe the binding modes of existing inhibitors and SHP-2 binding sites, summarize the characteristics of the sites involved in selectivity, and identify the suitable groups for interaction with the binding sites.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557520666200303130833
2020-07-01
2025-09-04
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557520666200303130833
Loading

  • Article Type:
    Review Article
Keyword(s): cancer; protein tyrosine kinases; PTKs; PTP; SHP-1; SHP-2
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test